Anlon Healthcare Limited is a research-driven pharmaceutical company specializing in the development and manufacture of **Active Pharmaceutical Ingredients (APIs)**, **Advanced Intermediates**, and **Nutraceuticals**. The company has established a dominant niche in high-value **Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)** and is currently executing a transformative shift toward a vertically integrated, multi-subsidiary group structure. --- ### **Core Product Portfolio & Specialized Chemistries** Anlon operates a high-compliance manufacturing model focused on molecules with high entry barriers. The company is the **only Indian manufacturer** and one of the largest global producers of **Loxoprofen**. * **Key API Molecules:** * **Loxoprofen Sodium Dihydrate:** Primary revenue driver; used for pain management and arthritis. * **Ketoprofen & Dexketoprofen Trometamol:** High-purity NSAIDs for global regulated markets. * **Ketoprofen Lysinate:** Specialized derivative for rapid-action pain relief. * **Intermediates & KSMs:** Backward integrated for **Loxoprofen Acid**, **BMPP**, **Ketonitrile**, and **3-(1-cyanoethyl)benzoic acid**. * **Nutraceuticals:** Portfolio of **20+ products**, including **L-Carnitine Tartrate**. * **Chemical Expertise:** Specialized technical capabilities in **Methylation**, **Friedel-Crafts chemistry**, **Bromination**, and high-pressure **Hydrogenation**. --- ### **Manufacturing Infrastructure & Capacity Expansion** The company is aggressively expanding its footprint in **Rajkot, Gujarat**, to address historical capacity constraints and support its **30% Revenue CAGR** target. | Facility / Entity | Current Status | Capacity (MTPA) | Strategic Focus | | :--- | :--- | :--- | :--- | | **Anlon Standalone** | Operational | **400** | Core APIs & Regulated Market supply. | | **Apiqo Organics** | Subsidiary (**67.48%**) | **700 – 800** | KSMs for Pharma & Agrochemicals. | | **Bizotic Lifescience**| Acquired (**56.67%**) | **300 – 400** | Domestic/Non-regulatory API & Job work. | | **Greenfield Project** | Commencing **Apr '26**| **1,200 – 1,300** | Large-scale multipurpose production. | | **Consolidated Total**| **Target FY27** | **~2,500+** | Aggregate group-wide capacity. | **Technical Specifications:** * **R&D:** 4 in-house centers with **11 fume cupboards** and scale-up assemblies (**20L to 200L**). * **Compliance:** **WHO-GMP** certified; Zero-liquid-discharge (ZLD) operations. * **Utilization:** Currently operating at **~84%** (Anlon) and **~80%** (Apiqo). --- ### **Strategic Growth Pillars: CDMO & Vertical Integration** Anlon is pivoting from a pure-play API manufacturer to a strategic partner for global innovators. * **CDMO Services:** Currently developing **3 molecules** for **2 global innovator companies** (Europe/Israel). One validation batch was dispatched in **February 2026**, with full commercialization expected by **Q3 FY27**. * **"China Plus One" Strategy:** The company has achieved **0% import dependency** on China for Key Starting Materials (KSMs), sourcing all materials indigenously to ensure supply chain security. * **Forward Integration:** Developing proprietary **gel and spray formulations** of Loxoprofen; **DCGI approval** is targeted for **FY28** to compete in the consumer healthcare segment. * **Circular Economy:** Diversifying into **E-Waste and Battery Recycling** to recover high-value metals (**Li, Co, Ni, Mn**) from "Black Mass," providing a secondary revenue stream and ESG hedge. --- ### **Global Regulatory Footprint** The company leverages a robust IP and filing strategy to penetrate high-margin regulated markets. * **DMF Filings:** **21 Drug Master Files** filed globally; targeting **3–5 new filings** in **FY27**. * **International Approvals:** * **Europe:** **CEP** for Ketoprofen; exports recently commenced to **Italy and Germany**. * **Brazil:** **ANVISA** approval for Loxoprofen Sodium Dihydrate. * **China:** **NMPA** approval for Loxoprofen Sodium Dihydrate. * **USA:** **FDA/DMF** submission for Ketoprofen in progress (Expected within **2 years**). --- ### **Financial Performance & Guidance** Following its **₹121.03 Cr IPO** in **August 2025**, Anlon has demonstrated significant margin expansion. | Metric | 9M FY26 (Actual) | FY27 (Target) | FY28 (Target) | | :--- | :--- | :--- | :--- | | **Total Income** | **₹121.32 Cr** | **₹370 – 380 Cr** | **₹650 – 700 Cr** | | **EBITDA Margin** | **26.84%** | **25% – 30%** | **30% – 33%** | | **PAT** | **₹18.02 Cr** | — | — | **Financial Strategy:** * **Debt Management:** Aiming to be **debt-free by Q3 FY27** (Current debt: **~₹4.5 Cr**). * **Working Capital:** Targeted reduction from **290 days** to **150–160 days** by **FY27**. * **Capital Allocation:** Re-routed **₹23.33 Cr** of IPO proceeds toward strategic acquisitions (**Apiqo/Bizotic**) to accelerate time-to-market. * **Shareholder Value:** Approved a **5-for-1 stock split** and a **1:1 bonus issue** in **April 2026** to improve liquidity. --- ### **Risk Factors & Mitigation** * **Credit Rating Fluctuations:** Brickwork Ratings recently **withdrawn** ratings following a "Non-Cooperating" status. Management is addressing this by closing term loans and consolidating banking relations with **NOCs** from major lenders like **PNB**. * **Integration Complexity:** The rapid acquisition of **Apiqo**, **Bizotic**, and **Remember India** poses organizational integration risks. The company plans to mitigate this by moving toward **100% ownership** via share swaps and eventual mergers. * **Concentration Risk:** **30-35%** of revenue is derived from the **Loxoprofen/Ketoprofen** series. Diversification into **7 new APIs** (Cardiac, CKD) and **Industrial Chemicals** is underway to de-risk the portfolio. * **Execution Risk:** The **₹100–110 Cr CapEx** for greenfield expansion requires disciplined project management to avoid cost overruns and ensure the **March 2027** operational deadline is met.